White Paper
COVID-19 Vaccine Post-Market Studies
The need for a flexible global approach.
Jul 20, 2020

The COVID-19 pandemic has rolled over the globe at a rate that has overwhelmed many governments and healthcare systems. The demand for a vaccine to help societies return to a new normal is loud, and there is enormous pressure on regulators to accommodate vaccine readiness. Pharma has risen to the challenge, with no less than 115 vaccines in development at unprecedented speed.

 

This paper discusses

  • Expectations for safety monitoring and the anticipated challenges
  • Learnings from past experience in monitoring H1N1 vaccines’ safety
  • Innovative and flexible prospective studies that leverage advanced direct-to-patient technology
Contact Us